These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26177791)

  • 41. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
    Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
    Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
    Atamaz F; Hepguler S; Akyildiz M; Karasu Z; Kilic M
    Osteoporos Int; 2006; 17(6):942-9. PubMed ID: 16550299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.
    Uchida S; Taniguchi T; Shimizu T; Kakikawa T; Okuyama K; Okaniwa M; Arizono H; Nagata K; Santora AC; Shiraki M; Fukunaga M; Tomomitsu T; Ohashi Y; Nakamura T
    J Bone Miner Metab; 2005; 23(5):382-8. PubMed ID: 16133688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.
    Jacobson DL; Lindsey JC; Gordon C; Hazra R; Spiegel H; Ferreira F; Amaral FR; Pagano-Therrien J; Gaur A; George K; Benson J; Siberry GK
    Clin Infect Dis; 2020 Aug; 71(5):1281-1288. PubMed ID: 31573608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
    Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA; Vinicola V
    Minerva Endocrinol; 2019 Dec; 44(4):344-350. PubMed ID: 31971357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
    HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.
    Grimnes G; Joakimsen R; Figenschau Y; Torjesen PA; Almås B; Jorde R
    Osteoporos Int; 2012 Jan; 23(1):201-11. PubMed ID: 21909730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand.
    Songpatanasilp T; Rojanasthien S; Sugkraroek P; Ongphiphadhanakul B; Robert L; Robert CS; Luevitoonvechkij S; Santora AC
    BMC Musculoskelet Disord; 2018 Nov; 19(1):392. PubMed ID: 30400864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
    Khan A; Dubois S; Khan AA; Zohair Rahman M; Ahmed Khan O; Syed HT; Derzko C
    J Obstet Gynaecol Can; 2014 Nov; 36(11):976-982. PubMed ID: 25574674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
    Vis M; Havaardsholm EA; Haugeberg G; Uhlig T; Voskuyl AE; van de Stadt RJ; Dijkmans BA; Woolf AD; Kvien TK; Lems WF
    Ann Rheum Dis; 2006 Nov; 65(11):1495-9. PubMed ID: 16606653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.